Glycomine’s Series C raise highlights investor confidence in the company amid pressure on the paediatric rare disease sector.

Glycomine has bagged a $115 million series C round to continue the progress of its lead candidate through phase 2 development ...

Researchers have found that patients with stage B heart failure characteristics and type 2 diabetes have impaired functional capacity.

The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (“ARI”) for the treatment of CNS rare metabolic diseases, including ...